research Reporting on Adverse Clinical Events
Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.
Search
for
Sort by
Research
450-480 / 1000+ results research Efectos del minoxidilo en formulación oral en pacientes barosensibles
Careful monitoring is needed when using oral minoxidil for hair loss due to potential side effects.
research Serenoa Repens for the Treatment of Capillary Disorders
Serenoa repens, a natural compound, can increase hair count and help repair capillaries, making it a promising treatment for hair loss.
research Finasteride: the first 5 alpha-reductase inhibitor.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
research Immunosuppressive treatment for proliferative lupus nephritis
Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.
research Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
research SIMULTANEOUS ESTIMATION OF MINOXIDIL AND FINASTERIDE BY RP-HPLC IN PRESENCE OF SOY LECITHIN EXCIPIENT IN THE LOTION DOSAGE FORM
research MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
research Anaphylactic shock associated with finasteride and terazosin
Combining finasteride and terazosin can cause severe allergic reactions.
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research A10.09 Safety data of four treatment regimens in early rheumatoid arthritis patients
All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.
research Association of prior 5-α-reductase inhibitor exposure with ICI benefit in metastatic RCC: Multicentre cohort with single-cell immune profiling.
Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
research Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches
Drug repositioning is a promising way to quickly develop new treatments, especially for rare diseases.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Actos, slings, finasteride, and the vaccine compensation solution.
research Anti-androgenic therapy with finasteride improves cardiac function, attenuates remodeling and reverts pathologic gene-expression after myocardial infarction in mice
Finasteride improves heart function and repairs damage after heart attack in mice.
research Fibrous Papule of the Face, Similar to Tuberous Sclerosis Complex-Associated Angiofibroma, Shows Activation of the Mammalian Target of Rapamycin Pathway: Evidence for a Novel Therapeutic Strategy?
Topical rapamycin may effectively treat fibrous papules on the face.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Gingival Hyperplasia Secondary to Everolimus Therapy
A woman developed thick gums from everolimus treatment after a kidney transplant.
research Association of 5-α reductase inhibitors and sexual dysfunction: A RADAR report
Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
research Finasteride and the 5-Alpha Reductase Inhibitors
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Finasteride for recurrent priapism in children and adolescents: A report on 5 cases
Finasteride may help treat recurrent priapism in children, but more research is needed.
research Using 5 alpha reductase inhibitors safely: What primary care physicians need to know
5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
research Baricitinib: From Rheumatoid Arthritis to COVID‐19
Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
research Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis
Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
research Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis
Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
research THE ROLE Of 5αR AND α1AR INHIBITORS IN MANAGEMENT OF BPH
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.